
浏览全部资源
扫码关注微信
纸质出版日期:2012
移动端阅览
常智玲, 何江, 李溥, 等. 降香舒心胶囊对气滞血瘀型不稳定型心绞痛患者血管内皮功能的影响[J]. 中国实验方剂学杂志, 2012,18(23):297-301.
CHANG Zhi-ling, HE Jiang, LI Pu, et al. Effects of Jiangxiang Shuxin Capsules on Endothelial Function in Patients with Unstable Angina Pectoris of Qi Stagnation and Blood Stasis Type[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(23): 297-301.
常智玲, 何江, 李溥, 等. 降香舒心胶囊对气滞血瘀型不稳定型心绞痛患者血管内皮功能的影响[J]. 中国实验方剂学杂志, 2012,18(23):297-301. DOI:
CHANG Zhi-ling, HE Jiang, LI Pu, et al. Effects of Jiangxiang Shuxin Capsules on Endothelial Function in Patients with Unstable Angina Pectoris of Qi Stagnation and Blood Stasis Type[J]. Chinese journal of experimental traditional medical formulae, 2012, 18(23): 297-301. DOI:
目的: 探讨降香舒心胶囊对气滞血瘀型不稳定型心绞痛的临床疗效及血管内皮功能的影响。 方法: 采用随机双盲安慰剂对照试验设计方法
选择158例气滞血瘀型不稳定型心绞痛患者随机分为治疗组81例和对照组77例
两组均采用最佳西医治疗方案
治疗组在西医治疗基础上口服降香舒心胶囊(4粒/次
3次/d)
对照组口服安慰剂胶囊(4粒/次
3次/d)。治疗疗程均为8周。并观察两组患者治疗前后心绞痛发作、中医证候以及检测血清一氧化氮(NO)、内皮素 (ET) 、血管性血友病因子(vWF)、超氧化物歧化酶(SOD)、丙二醛(MDA)水平及肱动脉血流介导的血管扩张变化率(FMD)。 结果: 治疗组与对照组心绞痛缓解总有效率分别为93.82%
68.83%
中医症状疗效总有效率分别为98.76%
66.23%;两组患者胸痛、胸闷、气短、心悸等各单项评分及总分与治疗前比较均降低(P<0.01)。治疗组与对照组比较
差异有统计学意义(P<0.05);与治疗前比较
治疗后两组患者血清ET
vWF降低
NO
FMD均升高(P<0.01))。治疗组血清SOD水平明显升高
MDA水平显著下降(P<0.01)
而对照组SOD和MDA水平无变化。 结论: 降香舒心胶囊能改善气滞血瘀型不稳定型心绞痛患者临床症状和血管内皮功能
是安全有效的辅助治疗药物。其机制可能与抗脂质过氧化作用有关。
Objective: To investigate the effect of Jiangxiang Shuxin capsules on vascular endothelium in patients with unstable angina pectoris (UAP) of Qi stagnation and blood stasis type. Method: A design of randomized
placebo-controlled
double-blind trial was adopted; 158 cases of UAP of Qi stagnation and blood stasis type were selected and randomly divided into treatment group and control group
with 81 cases in treatment group and 77 in control group. The best western medical therapy solution was applied to both groups
on which basis Jiangxiang Shuxin capsules and placebo capsules was used respectively; daily 3 times
each time 4 grain. The course of treatment was 8 weeks. To observe improvements of angina
comparison of symptom-complex and the levels of serum NO
endothelin-1(ET-1)
von willebrand factor(vWF)
superoxide dismutase(SOD)
malondialdehyda(MDA) from before treatment to after 8 weeks of treatment were observed
and the flow-mediated dilatation (FMD) in brachial artery was detected at the same time using ultrasonography. Result: The improvements of angina and total efficacious rate in treatment group was 93.82% and 98.76%
and control group was 68.83% and 66.23% respectively
the improvement of traditional Chinese medicine syndromes of the scores and total scores forchest pain
chest tightness
breathe hard
palpitations after treatment were lower than those before treatment in the two groups (P<0.01); score changes in treatment group were superior to that in control group (P<0.05); after treatment
the blood level of vWF and ET obviously decreased ( P<0.01)
levels of NO and FMD increased (P<0.01) in both groups. Levels of SOD significantly increased and MDA signif icantly decreased in the treated group (P<0.01)
while in the control group
no marked change was found in SOD and MDA. Conclusion: The results suggest that Jiangxiang Shuxin capsules was safe more effective
which could improve symptoms and the vascular endothe1ial function in patients with UAP of Qi stagnation and blood stasis type.Its mechanism might be associated with antioxidation in UAP.
0
浏览量
6
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621